ClinicalTrialsFinder
RecruitingNCT03004326

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Sponsor

Peter Merkel

Enrollment

50 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

VasculitisIgA VasculitisMicroscopic Polyangiitis (MPA)Eosinophilic Granulomatosis With Polyangiitis (EGPA)Granulomatosis With Polyangiitis (GPA)Polyarteritis Nodosa (PAN)Urticarial VasculitisCryoglobulinemic Vasculitis (CV)Drug-induced VasculitisIsolated Cutaneous Vasculitis

Summary

Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

Eligibility

Min Age: 5 Years

Inclusion Criteria12

  • Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis
  • Have a suspected or confirmed diagnosis of:
  • Cryoglobulinemic vasculitis (CV)
  • Drug-induced vasculitis
  • Eosinophilic granulomatosis with polyangiitis (EGPA)
  • IgA vasculitis
  • Isolated cutaneous vasculitis
  • Granulomatosis with polyangiitis (GPA)
  • Microscopic polyangiitis (MPA)
  • Polyarteritis nodosa (PAN)
  • Urticarial vasculitis
  • Be willing and able to provide written informed consent (or assent for those under

Exclusion Criteria7

  • You are less than five years old
  • Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy
  • You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dL
  • You have an uncontrolled disease that could prevent you from completing the study procedures
  • You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study
  • You are pregnant or nursing
  • You are not able to provide informed consent
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(10)

University of California, Los Angeles

Los Angeles, California, United States

Boston University School of Medicine

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Cleveland Clinic

Cleveland, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

University of Virginia

Charlottesville, Virginia, United States

St. Joseph's Healthcare

Hamilton, Ontario, Canada

University of Toronto Mount Sinai Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03004326

Related Trials

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

NCT050120331 location

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT0651288313 locations

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

NCT052514151 location

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT0702456314 locations

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT0632160130 locations